Details of Drug-Metabolizing Enzyme (DME)

General Information of Drug-Metabolizing Enzyme (DME) (ID: DEYEK78)

DME Name Nitric oxide synthase brain (NOS1)
Synonyms Peptidyl-cysteine S-nitrosylase NOS1; Neuronal NOS; Brain nitric oxide synthase; Constitutive NOS; bNOS; nNOS; N-NOS; NC-NOS; NOS type I; NOS1
Gene Name NOS1
UniProt ID
NOS1_HUMAN
INTEDE ID
DME0122
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
Gene ID
4842
EC Number EC: 1.14.13.39
Oxidoreductase
Oxygen paired donor oxidoreductase
NADH/NADPH donor oxidoreductase
EC: 1.14.13.39
Lineage Species: Homo sapiens
Kingdom: Metazoa
Phylum: Chordata
Class: Mammalia
Order: Primates
Family: Hominidae
Genus: Homo
Species: Homo sapiens
Sequence
MEDHMFGVQQIQPNVISVRLFKRKVGGLGFLVKERVSKPPVIISDLIRGGAAEQSGLIQA
GDIILAVNGRPLVDLSYDSALEVLRGIASETHVVLILRGPEGFTTHLETTFTGDGTPKTI
RVTQPLGPPTKAVDLSHQPPAGKEQPLAVDGASGPGNGPQHAYDDGQEAGSLPHANGLAP
RPPGQDPAKKATRVSLQGRGENNELLKEIEPVLSLLTSGSRGVKGGAPAKAEMKDMGIQV
DRDLDGKSHKPLPLGVENDRVFNDLWGKGNVPVVLNNPYSEKEQPPTSGKQSPTKNGSPS
KCPRFLKVKNWETEVVLTDTLHLKSTLETGCTEYICMGSIMHPSQHARRPEDVRTKGQLF
PLAKEFIDQYYSSIKRFGSKAHMERLEEVNKEIDTTSTYQLKDTELIYGAKHAWRNASRC
VGRIQWSKLQVFDARDCTTAHGMFNYICNHVKYATNKGNLRSAITIFPQRTDGKHDFRVW
NSQLIRYAGYKQPDGSTLGDPANVQFTEICIQQGWKPPRGRFDVLPLLLQANGNDPELFQ
IPPELVLEVPIRHPKFEWFKDLGLKWYGLPAVSNMLLEIGGLEFSACPFSGWYMGTEIGV
RDYCDNSRYNILEEVAKKMNLDMRKTSSLWKDQALVEINIAVLYSFQSDKVTIVDHHSAT
ESFIKHMENEYRCRGGCPADWVWIVPPMSGSITPVFHQEMLNYRLTPSFEYQPDPWNTHV
WKGTNGTPTKRRAIGFKKLAEAVKFSAKLMGQAMAKRVKATILYATETGKSQAYAKTLCE
IFKHAFDAKVMSMEEYDIVHLEHETLVLVVTSTFGNGDPPENGEKFGCALMEMRHPNSVQ
EERKSYKVRFNSVSSYSDSQKSSGDGPDLRDNFESAGPLANVRFSVFGLGSRAYPHFCAF
GHAVDTLLEELGGERILKMREGDELCGQEEAFRTWAKKVFKAACDVFCVGDDVNIEKANN
SLISNDRSWKRNKFRLTFVAEAPELTQGLSNVHKKRVSAARLLSRQNLQSPKSSRSTIFV
RLHTNGSQELQYQPGDHLGVFPGNHEDLVNALIERLEDAPPVNQMVKVELLEERNTALGV
ISNWTDELRLPPCTIFQAFKYYLDITTPPTPLQLQQFASLATSEKEKQRLLVLSKGLQEY
EEWKWGKNPTIVEVLEEFPSIQMPATLLLTQLSLLQPRYYSISSSPDMYPDEVHLTVAIV
SYRTRDGEGPIHHGVCSSWLNRIQADELVPCFVRGAPSFHLPRNPQVPCILVGPGTGIAP
FRSFWQQRQFDIQHKGMNPCPMVLVFGCRQSKIDHIYREETLQAKNKGVFRELYTAYSRE
PDKPKKYVQDILQEQLAESVYRALKEQGGHIYVCGDVTMAADVLKAIQRIMTQQGKLSAE
DAGVFISRMRDDNRYHEDIFGVTLRTYEVTNRLRSESIAFIEESKKDTDEVFSS
Function This enzyme has nitrosylase activity and mediates cysteine S-nitrosylation of cytoplasmic target proteins such SRR.
KEGG Pathway
Alzheimer's disease (hsa05010 )
Amyotrophic lateral sclerosis (ALS) (hsa05014 )
Apelin signaling pathway (hsa04371 )
Arginine and proline metabolism (hsa00330 )
Arginine biosynthesis (hsa00220 )
Calcium signaling pathway (hsa04020 )
Circadian entrainment (hsa04713 )
Long-term depression (hsa04730 )
Metabolic pathways (hsa01100 )
Phagosome (hsa04145 )
Relaxin signaling pathway (hsa04926 )
Salivary secretion (hsa04970 )
Reactome Pathway
Nitric oxide stimulates guanylate cyclase (R-HSA-392154 )
ROS and RNS production in phagocytes (R-HSA-1222556 )
Ion homeostasis (R-HSA-5578775 )

Molecular Interaction Atlas (MIA) of This DME

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DME
1 Approved Drug(s) Metabolized by This DME
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [26]

Molecular Expression Atlas (MEA) of This DME

Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This DME
Disease Name ICD 11 Studied Tissue p-value Fold-Change Z-score
Acute myelocytic leukaemia 2B33.1 Bone marrow 7.10E-01 -2.73E-02 -1.50E-01
Alopecia ED70 Skin from scalp 2.64E-01 -1.04E-01 -3.38E-01
Alzheimer's disease 8A20 Entorhinal cortex 3.36E-04 -1.87E-01 -5.75E-01
Ankylosing spondylitis FA92.0 Pheripheral blood 7.83E-01 2.93E-02 5.18E-01
Aortic stenosis BB70 Calcified aortic valve 9.70E-01 -1.71E-02 -2.61E-02
Apnea 7A40 Hyperplastic tonsil 2.32E-02 -5.83E-01 -1.32E+00
Arthropathy FA00-FA5Z Peripheral blood 1.84E-02 6.53E-02 6.25E-01
Asthma CA23 Nasal and bronchial airway 5.20E-01 2.14E-02 7.12E-02
Atopic dermatitis EA80 Skin 2.20E-01 8.48E-02 6.41E-01
Autism 6A02 Whole blood 7.08E-01 1.68E-02 7.40E-02
Autoimmune uveitis 9A96 Peripheral monocyte 4.54E-02 -2.68E-01 -2.90E+00
Autosomal dominant monocytopenia 4B04 Whole blood 6.79E-01 -3.17E-03 -2.50E-02
Bacterial infection of gingival 1C1H Gingival tissue 1.85E-12 -3.72E-01 -1.05E+00
Batten disease 5C56.1 Whole blood 1.85E-01 4.97E-02 6.84E-01
Behcet's disease 4A62 Peripheral blood 7.33E-02 3.32E-02 3.55E-01
Bipolar disorder 6A60-6A6Z Prefrontal cortex 6.10E-01 -1.68E-02 -9.39E-02
Bladder cancer 2C94 Bladder tissue 4.16E-05 5.04E-01 3.24E+00
Breast cancer 2C60-2C6Z Breast tissue 4.76E-15 -9.78E-02 -2.67E-01
Cardioembolic stroke 8B11.20 Whole blood 8.74E-03 7.17E-02 5.84E-01
Cervical cancer 2C77 Cervical tissue 7.81E-03 -1.09E-01 -6.70E-01
Childhood onset rheumatic disease FA20.Z Peripheral blood 4.37E-01 2.00E-02 1.30E-01
Chronic hepatitis C 1E51.1 Whole blood 3.44E-01 3.78E-02 6.12E-01
Chronic obstructive pulmonary disease CA22 Lung tissue 1.80E-02 1.15E-01 4.52E-01
Chronic obstructive pulmonary disease CA22 Small airway epithelium 4.54E-01 1.62E-02 1.10E-01
Chronic rhinosinusitis CA0A Sinus mucosa tissue 6.56E-01 -1.01E-02 -1.12E-01
Colon cancer 2B90 Colon tissue 4.68E-02 -4.53E-02 -2.05E-01
Coronary artery disease BA80-BA8Z Peripheral blood 2.46E-01 -1.70E-01 -6.48E-01
Diffuse large B-cell lymphoma 2A81 Tonsil tissue 4.35E-01 -1.09E-01 -8.02E-01
Endometriosis GA10 Endometrium tissue 3.27E-01 2.67E-01 7.55E-01
Familial hypercholesterolemia 5C80.00 Peripheral blood 3.40E-02 1.45E-01 1.52E+00
Familial hypercholesterolemia 5C80.00 Whole blood 3.24E-01 -3.17E-02 -1.81E-01
Gastric cancer 2B72 Gastric tissue 1.36E-01 -7.68E-01 -1.83E+00
Glioblastopma 2A00.00 Nervous tissue 6.41E-94 -5.77E-01 -1.63E+00
Glioma 2A00.0Y-2A00.0Z Brain stem tissue 1.37E-09 -9.45E-01 -3.96E+01
Glioma 2A00.0Y-2A00.0Z White matter tissue 4.58E-05 -5.94E-01 -1.67E+00
Head and neck cancer 2D42 Head and neck tissue 3.91E-02 7.93E-02 2.52E-01
HIV-associated neurocognitive impairment 8A2Y-8A2Z White matter tissue 1.35E-01 -1.55E-01 -3.91E-01
Huntington's disease 8A01.10 Whole blood 5.48E-01 -1.42E-02 -1.76E-01
Idiopathic pulmonary fibrosis CB03.4 Lung tissue 8.86E-01 4.78E-02 2.31E-01
Immunodeficiency 4A00-4A20 Peripheral blood 6.56E-01 3.16E-02 4.13E-01
Influenza 1E30 Whole blood 7.83E-02 1.35E-01 1.93E+00
Interstitial cystitis GC00.3 Bladder tissue 1.36E-01 4.18E-02 3.39E-01
Intracranial aneurysm 8B01.0 Intracranial artery 4.43E-02 -8.34E-02 -1.90E-01
Irritable bowel syndrome DD91.0 Rectal colon tissue 5.58E-01 5.40E-04 2.75E-03
Ischemic stroke 8B11 Peripheral blood 9.38E-01 -1.50E-03 -1.19E-02
Juvenile idiopathic arthritis FA24 Peripheral blood 2.21E-02 4.41E-02 3.01E-01
Lateral sclerosis 8B60.4 Skin 1.01E-02 1.02E-01 1.89E+00
Lateral sclerosis 8B60.4 Cervical spinal cord 9.79E-02 1.87E-01 1.02E+00
Liver cancer 2C12.0 Liver tissue 1.60E-11 -2.78E-01 -1.61E+00
Liver failure DB99.7-DB99.8 Liver tissue 1.94E-01 -9.05E-02 -4.98E-01
Lung cancer 2C25 Lung tissue 6.73E-15 -2.65E-01 -1.04E+00
Lupus erythematosus 4A40 Whole blood 3.14E-01 -5.10E-02 -1.12E-01
Major depressive disorder 6A70-6A7Z Hippocampus 2.47E-01 -8.47E-02 -4.62E-01
Major depressive disorder 6A70-6A7Z Whole blood 1.28E-01 5.17E-02 3.04E-01
Melanoma 2C30 Skin 9.99E-05 -1.70E-01 -4.02E-01
Multiple myeloma 2A83.1 Peripheral blood 3.18E-01 7.91E-02 6.92E-01
Multiple myeloma 2A83.1 Bone marrow 1.17E-03 -3.33E-01 -1.98E+00
Multiple sclerosis 8A40 Plasmacytoid dendritic cells 7.40E-01 5.10E-02 2.39E-01
Myelodysplastic syndrome 2A36-2A3Z Bone marrow 7.71E-01 4.83E-02 2.31E-01
Myelofibrosis 2A20.2 Whole blood 7.57E-03 1.37E-01 1.02E+00
Myocardial infarction BA41-BA50 Peripheral blood 1.94E-01 2.60E-01 6.14E-01
Myopathy 8C70.6 Muscle tissue 1.59E-04 -6.18E-01 -2.01E+00
Neonatal sepsis KA60 Whole blood 2.40E-03 2.94E-02 1.80E-01
Neuroectodermal tumour 2A00.11 Brain stem tissue 9.15E-06 -7.03E-01 -3.29E+00
Non-alcoholic fatty liver disease DB92 Liver tissue 7.76E-01 3.97E-02 2.84E-01
Obesity related type 2 diabetes 5A11 Omental adipose tissue 4.91E-01 2.34E-02 2.08E-01
Olive pollen allergy CA08.00 Peripheral blood 9.94E-02 1.42E-01 9.72E-01
Oral cancer 2B6E Oral tissue 1.35E-04 -4.42E-01 -6.78E-01
Osteoarthritis FA00-FA0Z Synovial tissue 3.18E-01 -7.52E-02 -1.52E-01
Osteoporosis FB83.1 Bone marrow 1.79E-02 1.30E-01 2.20E+00
Ovarian cancer 2C73 Ovarian tissue 3.95E-02 -3.69E-03 -2.79E-02
Pancreatic cancer 2C10 Pancreas 6.93E-03 -5.42E-01 -1.48E+00
Parkinson's disease 8A00.0 Substantia nigra tissue 9.42E-01 1.19E-01 2.43E-01
Pediatric respiratory syncytial virus infection CA40.11 Peripheral blood 9.70E-01 -3.20E-02 -2.33E-01
Pituitary cancer 2D12 Pituitary tissue 1.03E-01 -2.76E-01 -7.88E-01
Pituitary gonadotrope tumour 2D12 Pituitary tissue 5.24E-03 -4.92E-01 -2.67E+00
Polycystic ovary syndrome 5A80.1 Vastus lateralis muscle 2.09E-01 -3.72E-03 -2.32E-02
Polycythemia vera 2A20.4 Whole blood 7.63E-01 5.53E-03 4.37E-02
Pompe disease 5C51.3 Biceps muscle 2.40E-03 1.43E+00 2.56E+00
Preterm birth KA21.4Z Myometrium 3.03E-01 -8.70E-02 -9.09E-01
Prostate cancer 2C82 Prostate 5.72E-05 -8.70E-01 -1.39E+00
Psoriasis EA90 Skin 4.40E-08 -1.18E-01 -4.47E-01
Rectal cancer 2B92 Rectal colon tissue 1.63E-01 -2.15E-01 -8.37E-01
Renal cancer 2C90-2C91 Kidney 6.71E-04 -8.22E-01 -1.92E+00
Retinoblastoma 2D02.2 Uvea 4.97E-04 -3.04E-01 -3.01E+00
Rheumatoid arthritis FA20 Synovial tissue 2.47E-03 -7.07E-01 -1.74E+00
Rhinovirus infection CA42.1 Nasal epithelium tissue 5.52E-01 -1.52E-03 -1.41E-02
Schizophrenia 6A20 Prefrontal cortex 1.25E-02 -1.32E-01 -2.96E-01
Schizophrenia 6A20 Superior temporal cortex 9.10E-01 -3.02E-02 -3.70E-01
Scleroderma 4A42.Z Whole blood 6.30E-01 4.27E-02 2.51E-01
Seizure 8A60-8A6Z Whole blood 6.51E-01 7.60E-02 4.12E-01
Sensitive skin EK0Z Skin 2.06E-01 -4.50E-02 -2.98E-01
Sepsis with septic shock 1G41 Whole blood 1.03E-09 6.25E-02 4.10E-01
Shwachman-Diamond syndrome 3A70.0 Bone marrow 1.55E-01 6.03E-01 1.43E+00
Sickle cell disease 3A51.0-3A51.3 Peripheral blood 8.29E-01 3.50E-02 2.50E-01
Simpson golabi behmel syndrome LD2C Adipose tissue 7.52E-01 -9.93E-02 -1.03E+00
Sjogren's syndrome 4A43.2 Salivary gland tissue 8.60E-01 4.80E-03 1.60E-02
Skin cancer 2C30-2C3Z Skin 1.46E-68 -6.10E-01 -1.83E+00
Thrombocythemia 3B63 Whole blood 9.35E-02 1.06E-01 7.86E-01
Thrombocytopenia 3B64 Whole blood 7.34E-01 -4.34E-02 -7.47E-01
Thyroid cancer 2D10 Thyroid 1.71E-03 -1.31E-01 -4.71E-01
Tibial muscular dystrophy 8C75 Muscle tissue 4.23E-10 -1.52E+00 -4.92E+00
Tuberous sclerosis complex LD2D.2 Perituberal tissue 1.11E-01 2.14E-01 1.63E+00
Type 2 diabetes 5A11 Liver tissue 4.92E-01 -8.24E-02 -4.09E-01
Ureter cancer 2C92 Urothelium 1.34E-01 -9.01E-02 -5.20E-01
Uterine cancer 2C78 Endometrium tissue 1.77E-02 -8.49E-02 -2.70E-01
Vitiligo ED63.0 Skin 6.13E-02 4.24E-01 1.03E+00
------------------------------------------------------------------------------------
⏷ Show the Full List of DME Expression Under 107 Diseases

The Drug Therapeutic Target (DTT) Role of This DME

DME DTT Name Nitric-oxide synthase brain (NOS1) DTT Info
DME DTT Type Clinical trial
2 Clinical Trial Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
NXN-188 DMMBAIH Migraine 8A80 Phase 2 [1]
NXN-462 DMWVBS2 Headache 8A80-8A84 Phase 2 [2]
1 Discontinued Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
L-NIL DM6Y49D N. A. N. A. Terminated [3]
122 Investigative Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
((E)-7-But-2-enyl)-azepan-(2Z)-ylideneamine DMCW65Q Discovery agent N.A. Investigative [4]
(+/-)-2-Methyl-1-(1-phenylethyl)-1H-imidazole DMJ6MPO Discovery agent N.A. Investigative [5]
(4S,5R)-4,5-Diethyl-oxazolidin-(2Z)-ylideneamine DMM6QV5 Discovery agent N.A. Investigative [6]
(4S,5R)-4,5-Dimethyl-oxazolidin-(2Z)-ylideneamine DM0V9HB Discovery agent N.A. Investigative [6]
(4S,5S)-4,5-Diethyl-oxazolidin-(2Z)-ylideneamine DM1VJUZ Discovery agent N.A. Investigative [6]
(5-Imino-[1,4]thiazepan-3-yl)-methanol DMBKZDJ Discovery agent N.A. Investigative [7]
(5S,6R)-[Octahydro-quinolin-(2E)-ylidene]amine DMT9CXD Discovery agent N.A. Investigative [8]
(5S,6S)-[Octahydro-quinolin-(2E)-ylidene]amine DMP4UC1 Discovery agent N.A. Investigative [8]
(6r,1'r,2's)-5,6,7,8 Tetrahydrobiopterin DMOD9R7 Discovery agent N.A. Investigative [9]
(R)-3-Propyl-[1,4]thiazepan-(5E)-ylideneamine DM1Y9MZ Discovery agent N.A. Investigative [7]
(S)-2-Amino-5-(N-methyl-guanidino)-pentanoic acid DMZSWDM Discovery agent N.A. Investigative [10]
(S)-3-Propyl-[1,4]thiazepan-(5E)-ylideneamine DMIG9H3 Discovery agent N.A. Investigative [7]
(S)-6-Amino-2-(2-imino-ethylamino)-hexanoic acid DMG58HM Discovery agent N.A. Investigative [7]
1-(2-amino-benzothiazol-5-yl)-2-ethyl-isothiourea DMAE8BF Discovery agent N.A. Investigative [11]
1-(2-amino-benzothiazol-6-yl)-2-ethyl-isothiourea DMCSHRL Discovery agent N.A. Investigative [11]
1-(Benzhydrylamino)ethaniminium bromide DMOJC9Z Discovery agent N.A. Investigative [5]
1-Benzyl-2-methyl-1H-imidazole DMEVO6M Discovery agent N.A. Investigative [5]
1-[(3-Methoxybenzyl)amino]ethaniminium chloride DM7U0XW Discovery agent N.A. Investigative [5]
1400W DMLZT64 Discovery agent N.A. Investigative [12]
2'-Monophosphoadenosine 5'-Diphosphoribose DME9S8M Discovery agent N.A. Investigative [9]
2-(2-Amino-ethyl)-7-imino-azepane DM3JM7V Discovery agent N.A. Investigative [4]
2-amino-4,6-dimethylpyridine DMVJXQ9 Discovery agent N.A. Investigative [13]
2-amino-4-methylpyridine DM1OED2 Discovery agent N.A. Investigative [14]
2-Amino-5-(N-nitro-guanidino)-pentanoic acid DMDUZ2H Discovery agent N.A. Investigative [10]
2-aminopyridine DMQIC3L Discovery agent N.A. Investigative [13]
2-Aminothiazoline DM9YCAH Discovery agent N.A. Investigative [15]
2-Methyl-[1,4]thiazepan-(5E)-ylideneamine DMX1IC4 Discovery agent N.A. Investigative [7]
3,4-Dihydro-1H-quinolin-(2E)-ylideneamine DM0I6UT Discovery agent N.A. Investigative [8]
3,4-Dimethyl-pyrrolidin-(2Z)-ylideneamine DMMO6QI Discovery agent N.A. Investigative [15]
3-(2-Amino-ethyl)-5-imino-[1,4]oxazepane DM95R6O Discovery agent N.A. Investigative [4]
3-(2-Nitro-ethyl)-[1,4]oxazepan-(5Z)-ylideneamine DMYXQ7L Discovery agent N.A. Investigative [4]
3-Bromo-1H-indazole-7-carbonitrile DMZGWL2 Discovery agent N.A. Investigative [16]
3-bromo-7-nitro-1H-indazole DMM7DHB Discovery agent N.A. Investigative [9]
3-Butyl-[1,4]thiazepan-(5E)-ylideneamine DM6A80U Discovery agent N.A. Investigative [7]
3-Ethyl-[1,4]thiazepan-(5E)-ylideneamine DMX2JKQ Discovery agent N.A. Investigative [7]
3-Isobutyl-[1,4]thiazepan-(5E)-ylideneamine DMQXP7C Discovery agent N.A. Investigative [7]
3-Methyl-pyrrolidin-(2Z)-ylideneamine DMHVUF8 Discovery agent N.A. Investigative [15]
3-Methyl-[1,4]thiazepan-(5E)-ylideneamine DMCOH46 Discovery agent N.A. Investigative [7]
3-Propyl-[1,4]thiazepan-(5E)-ylideneamine DMYACO7 Discovery agent N.A. Investigative [7]
4,5,6,7-tetrafluoro-3-methyl-1H-indazole DMTC7J2 Discovery agent N.A. Investigative [17]
4,5-Dimethyl-pyrrolidin-(2Z)-ylideneamine DMB9CJM Discovery agent N.A. Investigative [15]
4-bromo-1H-indazole DM81D90 Discovery agent N.A. Investigative [18]
4-Butyl-thiazolidin-(2E)-ylideneamine DMKU4TR Discovery agent N.A. Investigative [15]
4-chloro-1H-indazole DMHNSXP Discovery agent N.A. Investigative [18]
4-Ethyl-3-methyl-pyrrolidin-(2Z)-ylideneamine DM5G3NU Discovery agent N.A. Investigative [15]
4-Ethyl-5-methyl-pyrrolidin-(2Z)-ylideneamine DMOAQ1E Discovery agent N.A. Investigative [15]
4-Ethyl-oxazolidin-(2Z)-ylideneamine DMG0Y3W Discovery agent N.A. Investigative [6]
4-Ethyl-pyrrolidin-(2Z)-ylideneamine DMYIWAH Discovery agent N.A. Investigative [15]
4-iodo-1H-indazole DMKZQ3I Discovery agent N.A. Investigative [18]
4-Isopropyl-pyrrolidin-(2Z)-ylideneamine DMVTEOQ Discovery agent N.A. Investigative [15]
4-Methyl-5-propyl-pyrrolidin-(2Z)-ylideneamine DMN8Z3C Discovery agent N.A. Investigative [15]
4-methyl-6-propylpyridin-2-amine DMY04D1 Discovery agent N.A. Investigative [14]
4-Methyl-oxazolidin-(2Z)-ylideneamine DME7W0Q Discovery agent N.A. Investigative [6]
4-Methyl-piperidin-(2E)-ylideneamine DMNMXCE Discovery agent N.A. Investigative [8]
4-Methyl-pyrrolidin-(2Z)-ylideneamine DM0YS36 Discovery agent N.A. Investigative [15]
4-[(2-Methyl-1H-imidazol-1-yl)methyl]pyridine DM8BPTQ Discovery agent N.A. Investigative [5]
5-bromo-1H-indazole DM2QPHE Discovery agent N.A. Investigative [18]
5-Bromomethyl-oxazolidin-(2Z)-ylideneamine DMH908V Discovery agent N.A. Investigative [6]
5-chloro-1H-indazole DMOCYDU Discovery agent N.A. Investigative [18]
5-Ethyl-3-methyl-pyrrolidin-(2Z)-ylideneamine DMS9TFC Discovery agent N.A. Investigative [15]
5-Ethyl-4-methyl-pyrrolidin-(2Z)-ylideneamine DMQWOIG Discovery agent N.A. Investigative [15]
5-Ethyl-4-propyl-pyrrolidin-(2Z)-ylideneamine DMSA8X2 Discovery agent N.A. Investigative [15]
5-Ethyl-oxazolidin-(2Z)-ylideneamine DM8Y4G5 Discovery agent N.A. Investigative [6]
5-iodo-1H-indazole DM4NQY6 Discovery agent N.A. Investigative [18]
5-Methyl-oxazolidin-(2Z)-ylideneamine DMBQS31 Discovery agent N.A. Investigative [6]
5-Methyl-pyrrolidin-(2Z)-ylideneamine DM4QB3G Discovery agent N.A. Investigative [15]
5-N-Allyl-Arginine DMOSKJ8 Discovery agent N.A. Investigative [9]
6-(2-Fluoropropyl)-4-methylpyridin-2-amine DME1JLM Discovery agent N.A. Investigative [19]
6-(3-Fluoropropyl)-4-methylpyridin-2-amine DMTJPZU Discovery agent N.A. Investigative [19]
6-bromo-1H-indazole DMU9WG0 Discovery agent N.A. Investigative [18]
6-chloro-1H-indazole DMKCBIL Discovery agent N.A. Investigative [18]
6-isobutyl-4-methylpyridin-2-amine DM2XB68 Discovery agent N.A. Investigative [19]
7-(2-Nitro-ethyl)-azepan-(2Z)-ylideneamine DMK28IS Discovery agent N.A. Investigative [4]
7-bromo-1H-indazole DMYBNCO Discovery agent N.A. Investigative [18]
7-Butyl-azepan-(2Z)-ylideneamine DMVTK0A Discovery agent N.A. Investigative [4]
7-chloro-1H-indazole DMX8DZM Discovery agent N.A. Investigative [18]
7-Methoxy-1H-indazole DMTFBCU Discovery agent N.A. Investigative [20]
7-Methyl-[1,4]thiazepan-(5E)-ylideneamine DMUCJA6 Discovery agent N.A. Investigative [7]
7-nitro-1H-indazole DMW4XKQ Discovery agent N.A. Investigative [17]
Acetate Ion DMD08RH Discovery agent N.A. Investigative [9]
Alpha-D-Mannose DMF5DLW Discovery agent N.A. Investigative [9]
AR-C102222 DMWVULN Discovery agent N.A. Investigative [14]
AR-C133057XX DM71WQT Discovery agent N.A. Investigative [14]
Azepan-(2Z)-ylideneamine DMZHV39 Discovery agent N.A. Investigative [4]
Azocan-(2Z)-ylideneamine DMQ13PZ Discovery agent N.A. Investigative [4]
Azonan-(2Z)-ylideneamine DMTQSNK Discovery agent N.A. Investigative [10]
EUSYNSTYELAMIDE B DMXBGSL Discovery agent N.A. Investigative [21]
Eusynstyelamide C DM6ODAS Discovery agent N.A. Investigative [21]
Flavin-Adenine Dinucleotide DM5S4GK Discovery agent N.A. Investigative [9]
Formic Acid DMNFZC6 Discovery agent N.A. Investigative [9]
Heme DMGC287 Discovery agent N.A. Investigative [12]
Hexahydro-cyclopenta[b]pyrrol-(2Z)-ylideneamine DMNZLD6 Discovery agent N.A. Investigative [15]
Hexahydro-cyclopenta[c]pyrrol-(1Z)-ylideneamine DMG0UVT Discovery agent N.A. Investigative [15]
Hexahydro-pyrrolizin-(3E)-ylideneamine DMIB3J2 Discovery agent N.A. Investigative [15]
L-NIO DME9FAV Discovery agent N.A. Investigative [22]
N*1*-(5-Methyl-2-nitro-phenyl)-butane-1,4-diamine DM8JQEO Discovery agent N.A. Investigative [23]
N-(5-Amino-6-oxo-heptyl)-acetamidine DM47XR8 Discovery agent N.A. Investigative [15]
N-Butyl-N'-Hydroxyguanidine DMKCX5N Discovery agent N.A. Investigative [9]
N-Isopropyl-N'-Hydroxyguanidine DMIVO8P Discovery agent N.A. Investigative [9]
N-omega-allyl-L-arginine DM0BPCT Discovery agent N.A. Investigative [22]
N-Omega-Hydroxy-L-Arginine DMOXQ3N Discovery agent N.A. Investigative [9]
N-omega-propargyl-L-arginine DM9X3B7 Discovery agent N.A. Investigative [22]
N-Omega-Propyl-L-Arginine DM4X0WY Discovery agent N.A. Investigative [9]
N5-(1-Imino-3-Butenyl)-L-Ornithine DMY3O6N Discovery agent N.A. Investigative [9]
N5-(1-iminobut-3-enyl)-L-ornithine DMB62OI Discovery agent N.A. Investigative [22]
N5-(1-iminobutyl)-L-ornithine DMT893N Discovery agent N.A. Investigative [22]
N5-(1-iminopent-3-enyl)-L-ornithine DM0TS21 Discovery agent N.A. Investigative [22]
N5-(1-iminopropyl)-L-ornithine DM05O7J Discovery agent N.A. Investigative [22]
Nitroarginine DM7T80N N. A. N. A. Investigative [24]
Octahydro-isoindol-(1Z)-ylideneamine DM4C70S Discovery agent N.A. Investigative [15]
Piperidin-(2E)-ylideneamine DMN8OR2 Discovery agent N.A. Investigative [8]
Pyrrolidin-(2Z)-ylideneamine DMS4ZFU Discovery agent N.A. Investigative [15]
S-Ethyl-N-Phenyl-Isothiourea DM6DT9Z Discovery agent N.A. Investigative [12]
S-Ethyl-N-[4-(Trifluoromethyl)Phenyl]Isothiourea DM49AYM Discovery agent N.A. Investigative [12]
Tetrahydro-pyrimidin-2-ylideneamine DMMU6WQ Discovery agent N.A. Investigative [10]
THIOCITRULLINE DM7X8MH Discovery agent N.A. Investigative [25]
[1,3]Oxazinan-(2E)-ylideneamine DMDX6W4 Discovery agent N.A. Investigative [10]
[1,3]Thiazinan-(2E)-ylideneamine DMOEIHC Discovery agent N.A. Investigative [10]
[1,4]Oxazepan-(3E)-ylideneamine DMX58NK Discovery agent N.A. Investigative [7]
[1,4]Oxazepan-(5E)-ylideneamine DMMUZVS Discovery agent N.A. Investigative [7]
[1,4]Thiazepan-(3E)-ylideneamine DMCBFJQ Discovery agent N.A. Investigative [7]
[1,4]Thiazepan-(5E)-ylideneamine DMFQ0Z4 Discovery agent N.A. Investigative [7]
⏷ Show the Full List of 122 Investigative Drug(s)

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 ClinicalTrials.gov (NCT01748877) Efficacy, Tolerability, and Safety of NXN-462 in Patients With Post-Herpetic Neuralgia. U.S. National Institutes of Health.
3 Discovery of a series of aminopiperidines as novel iNOS inhibitors. Bioorg Med Chem Lett. 2008 Jan 1;18(1):336-43.
4 Selective heterocyclic amidine inhibitors of human inducible nitric oxide synthase. Bioorg Med Chem Lett. 2001 Oct 8;11(19):2651-3.
5 N-Substituted acetamidines and 2-methylimidazole derivatives as selective inhibitors of neuronal nitric oxide synthase. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6495-9.
6 4,5-Disubstituted-1,3-oxazolidin-2-imine derivatives: a new class of orally bioavailable nitric oxide synthase inhibitor. Bioorg Med Chem Lett. 2004 Jan 19;14(2):313-6.
7 Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11.
8 Bicyclic amidine inhibitors of nitric oxide synthase: discovery of perhydro-iminopyrindine and perhydro-iminoquinoline as potent, orally active inh... Bioorg Med Chem Lett. 2005 Apr 15;15(8):1997-2001.
9 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
10 2-Iminopiperidine and other 2-iminoazaheterocycles as potent inhibitors of human nitric oxide synthase isoforms. J Med Chem. 1996 Feb 2;39(3):669-72.
11 Novel 2-aminobenzothiazoles as selective neuronal nitric oxide synthase inhibitors. Bioorg Med Chem Lett. 2007 May 1;17(9):2540-4.
12 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
13 L337H mutant of rat neuronal nitric oxide synthase resembles human neuronal nitric oxide synthase toward inhibitors. J Med Chem. 2009 Jul 23;52(14):4533-7.
14 Anchored plasticity opens doors for selective inhibitor design in nitric oxide synthase. Nat Chem Biol. 2008 Nov;4(11):700-7.
15 Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44.
16 Inhibitory effects of a series of 7-substituted-indazoles toward nitric oxide synthases: particular potency of 1H-indazole-7-carbonitrile. Bioorg Med Chem. 2008 Jun 1;16(11):5962-73.
17 Fluorinated indazoles as novel selective inhibitors of nitric oxide synthase (NOS): synthesis and biological evaluation. Bioorg Med Chem. 2009 Sep 1;17(17):6180-7.
18 4-substituted indazoles as new inhibitors of neuronal nitric oxide synthase. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3177-80.
19 Design and synthesis of 2-amino-4-methylpyridine analogues as inhibitors for inducible nitric oxide synthase and in vivo evaluation of [18F]6-(2-fl... J Med Chem. 2009 Apr 23;52(8):2443-53.
20 Inhibition of neuronal nitric oxide synthase by 7-methoxyindazole and related substituted indazoles. Bioorg Med Chem Lett. 2001 May 7;11(9):1153-6.
21 Eusynstyelamides A, B, and C, nNOS inhibitors, from the ascidian Eusynstyela latericius. J Nat Prod. 2009 Jun;72(6):1115-20.
22 Structure-activity relationship of novel and known inhibitors of human dimethylarginine dimethylaminohydrolase-1: alkenyl-amidines as new leads. Bioorg Med Chem. 2008 Dec 15;16(24):10205-9.
23 Nitroaromatic amino acids as inhibitors of neuronal nitric oxide synthase. J Med Chem. 1998 Jul 2;41(14):2636-42.
24 Crystal structure of nitric oxide synthase bound to nitro indazole reveals a novel inactivation mechanism. Biochemistry. 2001 Nov 13;40(45):13448-55.
25 Evaluation of 3-substituted arginine analogs as selective inhibitors of human nitric oxide synthase isozymes. Bioorg Med Chem Lett. 2005 Jun 2;15(11):2881-5.
26 The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage. FASEB J. 2004 Apr;18(6):664-75.